Quarterly report pursuant to Section 13 or 15(d)

Schedule of Noncontrolling Interest of Stockholders' Equity (Details)

v3.22.2.2
Schedule of Noncontrolling Interest of Stockholders' Equity (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]          
NCI – equity (deficit) – beginning of period     $ 17,752    
Investment in Veris Health Inc.   $ 6   $ 6  
Net loss attributable to NCI - Lucid Diagnostics Inc. $ (3,576) (1,199) (6,337) (1,877)  
NCI – equity (deficit) – end of period 19,426   19,426   $ 17,752
Noncontrolling Interest [Member]          
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]          
NCI – equity (deficit) – beginning of period     17,752 (2,369) (2,369)
Investment in Veris Health Inc.   $ 6 $ 6 6
Net loss attributable to NCI - Lucid Diagnostics Inc.     (5,711)   (5,779)
Net loss attributable to NCI – Solys Diagnostics Inc.     (6)  
Net loss attributable to NCI – Veris Health Inc.     (620)  
Impact of subsidiary equity transactions     229   16,760
Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise     688  
Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan     7,091   9,134
Stock-based compensation expense - Veris Health Inc. 2021 Equity Plan     3  
NCI – equity (deficit) – end of period $ 19,426   $ 19,426   $ 17,752